AI in cancer diagnostics: recurrence prediction, bladder cancer risk, oral tumours, a pathology engine and breast screening
New studies report that AI can predict pancreatic cancer recurrence from pathology slides and detect signs of bladder cancer risk with 91% accuracy. Deciphex has launched CipherX, an AI engine for pathology questions, and Lord's Mark is advancing its AI breast screening technology towards final clinical trials in the USA, Great Britain and Europe.
Who is affected and how
- doctor
- Doctors should follow developments in pathology and screening AI tools; validation data are needed before clinical adoption.
- medtech company
- Breast screening AI heading into final clinical trials and new pathology engines are sharpening product competition.
Sources
- AI scans pathology slides to predict pancreatic cancer recurrencehealthcare-in-europe.com · Sep 21, 2026
- Observational study finds AI detects bladder cancer risk signs with 91% accuracy — Evidence Review | News | The Consensus Research Librarytopics.consensus.app · Sep 23, 2026
- AI could offer more precise breast cancer recurrence risk, study findsmedicalnewstoday.com · Sep 27, 2026
- Early diagnosis of oral cavity tumors using AI | Università degli Studi di Sassariuniss.it · Sep 25, 2026
- AI for early diagnosis of oral cancers, a study by the University of Sassariunionesarda.it · Sep 25, 2026
- Lord’s Mark Advances AI-Powered Breast Cancer Screening Technology Towards Final Clinical Trials Across USA, Great Britain and Europeani news · Sep 23, 2026
- Lord’s Mark advances AI breast cancer screening towards clinical trialsthe economic times · Sep 25, 2026
- Deciphex launches CipherX: a step beyond foundation models, an AI engine for any pathology questionimt.ie · Sep 22, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.